Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?
JV Melo, DM Ross - Hematology 2010, the American Society of …, 2011 - ashpublications.org
Patients with chronic myeloid leukemia (CML) who have achieved a complete molecular
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …
Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?
JV Melo, DM Ross - … the Education Program of the American …, 2011 - research.sahmri.org.au
Patients with chronic myeloid leukemia (CML) who have achieved a complete molecular
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …
Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?
J Melo, D Ross - Hematology: American Society of …, 2011 - researchnow.flinders.edu.au
Patients with chronic myeloid leukemia (CML) who have achieved a complete molecular
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …
[引用][C] Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?
M JV - Hematology Am Soc Hematol Educ Program, 2011 - cir.nii.ac.jp
Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia : can
we aim at a cure? | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
we aim at a cure? | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?
JV Melo, DM Ross - Hematology. American Society of …, 2011 - pubmed.ncbi.nlm.nih.gov
Patients with chronic myeloid leukemia (CML) who have achieved a complete molecular
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …
Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?
JV Melo, DM Ross - Hematology. American Society of Hematology …, 2011 - europepmc.org
Patients with chronic myeloid leukemia (CML) who have achieved a complete molecular
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …
[PDF][PDF] Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?
JV Melo, DM Ross - scholar.archive.org
Patients with chronic myeloid leukemia (CML) who have achieved a complete molecular
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …
response (CMR) defined by no detectable BCR-ABL mRNA on imatinib (IM) treatment often …
[引用][C] Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?
M JV - Hematology Am Soc Hematol Educ Program, 2011 - cir.nii.ac.jp
Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia : can
we aim at a cure? | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …
we aim at a cure? | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細 …